$PULM News

Pulmatrix Receives Notice Of Allowance For U.S. Patent Covering Dry Powder Dihydroergotamine Formulations For Migraine

Eos SENOLYTIX CEO To Deliver Industry Keynote On Advancing Mitochondrial-Targeted Geropeptide Medicine; Co. Expects To Close Pulmatrix Merger In Q4

Pulmatrix Announces Second Quarter 2026 Financial Results and Progress on Merger

Pulmatrix Q2 EPS $(0.29) Up From $(0.42) YoY

Pulmatrix Announces First Quarter 2026 Financial Results

Pulmatrix Q1 EPS $(0.32) Up From $(0.50) YoY

Pulmatrix Announces Closing of Preferred Stock Transaction as Part of Planned Merger

Pulmatrix and Eos SENOLYTIX Announce Merger Agreement to Advance Novel Mitochondrial Therapies to Improve Healthspan

Pulmatrix shares are trading lower after the company announced it will acquire Eos, a developer of novel gerotherapeutic peptides targeting mitochondrial dysfunction in aging-related diseases.

Pulmatrix shares are trading lower after the company announced it will acquire Eos, a developer of novel gerotherapeutic peptides targeting mitochondrial dysfunction in aging-related diseases.

Wave crashes on obesity drug update; Kodiak’s reboot pays dividends

Trading Halt: Halt status updated at 8:25:00 AM ET: Quotation Resumption: News and Resumption Times

Pulmatrix Signs Agreement To Acquire Eos SENOLYTIX; Financial Terms Undisclosed

Trading Halt: Halted at 7:59:18 a.m. ET - Trading Halt: Halt News Pending

Gyre Therapeutics to acquire Cullgen in $300M all-stock transaction

Pulmatrix shares are trading lower after a planned acquisition was rejected.

Pulmatrix Announces Termination of Prior Planned Merger and Continues Pursuit of Alternative Merger Opportunities

Cullgen Cancels Planned Merger With Pulmatrix; Pulmatrix To Continue Search For Acquisition

Pulmatrix Announces Year-End and Fourth Quarter 2025 Financial Results

Pulmatrix Q4 EPS $(0.25) Up From $(0.55) YoY